Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Cell Death Dis ; 6: e1786, 2015 Jun 11.
Article in English | MEDLINE | ID: mdl-26068794

ABSTRACT

High-mobility group box 1 (HMGB1) is an inflammatory molecule that has a critical role in the initiation and progression of malignant mesothelioma (MM). Aspirin (acetylsalicylic acid, ASA) is the most widely used nonsteroidal anti-inflammatory drug that reduces the incidence, metastatic potential and mortality of many inflammation-induced cancers. We hypothesized that ASA may exert anticancer properties in MM by abrogating the carcinogenic effects of HMGB1. Using HMGB1-secreting and -non-secreting human MM cell lines, we determined whether aspirin inhibited the hallmarks of HMGB1-induced MM cell growth in vitro and in vivo. Our data demonstrated that ASA and its metabolite, salicylic acid (SA), inhibit motility, migration, invasion and anchorage-independent colony formation of MM cells via a novel HMGB1-mediated mechanism. ASA/SA, at serum concentrations comparable to those achieved in humans taking therapeutic doses of aspirin, and BoxA, a specific inhibitor of HMGB1, markedly reduced MM growth in xenograft mice and significantly improved survival of treated animals. The effects of ASA and BoxA were cyclooxygenase-2 independent and were not additive, consistent with both acting via inhibition of HMGB1 activity. Our findings provide a rationale for the well documented, yet poorly understood antitumorigenic activity of aspirin, which we show proceeds via HMGB1 inhibition. Moreover, the use of BoxA appears to allow a more efficient HMGB1 targeting while eluding the known gastrointestinal side effects of ASA. Our findings are directly relevant to MM. Given the emerging importance of HMGB1 and its tumor-promoting functions in many cancer types, and of aspirin in cancer prevention and therapy, our investigation is poised to provide broadly applicable information.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/therapeutic use , HMGB1 Protein/antagonists & inhibitors , Lung Neoplasms/drug therapy , Mesothelioma/drug therapy , Salicylic Acid/therapeutic use , 3T3 Cells , Animals , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Epithelial-Mesenchymal Transition/drug effects , Female , HMGB1 Protein/metabolism , Lung Neoplasms/metabolism , Mesothelioma/metabolism , Mesothelioma, Malignant , Mice , Mice, Knockout , Mice, SCID , Neoplasm Invasiveness/pathology , Xenograft Model Antitumor Assays
2.
Eur Respir J ; 34(6): 1399-407, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19460788

ABSTRACT

Malignant mesothelioma is an asbestos-related, aggressive tumour, resistant to most anticancer therapies. Akt is a key mediator of mesothelioma cell survival and chemoresistance. This study aimed to clarify the mechanism by which taurolidine (TN), a known synthetic compound with antimicrobial and antineoplastic properties, leads to mesothelioma cell death. Apoptosis was studied by annexin V binding, cell cycle analysis, caspase-8 activation, poly(ADP-ribose) polymerase (PARP) cleavage and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling (TUNEL). Oxidative stress was measured by nitrite production and DNA oxidative damage. Protein expression and phosphorylation were evaluated by immunoprecipitation and immunoblotting. TN induces cell death of mesothelioma cells, but not of non-neoplastic human mesothelial cells. After TN treatment of mesothelioma cells, Akt but not extracellular signal-regulated kinase (Erk) 1/2 activity is inhibited a in time- and dose-dependent manner. Protein phosphatase (PP)1alpha and PP2A are activated several hours after drug addition. Apoptosis induced by TN is driven by oxidative stress and cell exposure to sulfydryl donors, such as glutathione monoethylester and l-N-acetylcysteine, significantly reduced pro-apoptotic effects and Akt inhibition. Conversely, expression of constitutively activated Akt did not affect cytoxicity elicited by TN, which retained its ability to inhibit the kinase. TN induces mesothelioma cell death via oxidative stress, accompanied by inhibition of Akt signalling. This provides a promising molecular rationale for TN as local treatment of malignant mesothelioma.


Subject(s)
Antineoplastic Agents/therapeutic use , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Mesothelioma/drug therapy , Mesothelioma/pathology , Oxidative Stress , Taurine/analogs & derivatives , Thiadiazines/therapeutic use , Apoptosis , Cell Death , Cell Line, Tumor , Cells, Cultured , DNA/metabolism , Fibroblasts/metabolism , Humans , In Situ Nick-End Labeling , Proto-Oncogene Proteins c-akt/metabolism , Taurine/therapeutic use , Time Factors
3.
Int J Cancer ; 121(1): 12-20, 2007 Jul 01.
Article in English | MEDLINE | ID: mdl-17354240

ABSTRACT

Malignant mesothelioma (MM) is an aggressive tumor associated with environmental or occupational exposure to asbestos fibers. Erionite is a fibrous zeolite, morphologically similar to asbestos and it is assumed to be even more carcinogenic. Onset and progression of MM has been suggested as the result of the cooperation between asbestos and other cofactors, such as SV40 virus infection. Nevertheless, several cases of MM were associated with environmental exposure to erionite in Turkey, where SV40 was never isolated in MM specimens. We show here that erionite is poorly cytotoxic, induces proliferating signals and high growth rate in human mesothelial cells (HMC). Long term exposure to erionite, but not to asbestos fibers, transforms HMC in vitro, regardless of the presence of SV40 sequences, leading to foci formation in cultured monolayers. Cells derived from foci display constitutive activation of Akt, NF-kappaB and Erk1/2, show prolonged survival and a deregulated cell cycle, involving cyclin D1 and E overexpression. Our results reveal that erionite is able per se to turn HMC into transformed highly proliferating cells and disclose the carcinogenic properties of erionite, prompting for a careful evaluation of environmental exposure to these fibers. The genetic predisposition to the effect of erionite is a separate subject for investigation.


Subject(s)
Asbestos/toxicity , Cell Transformation, Neoplastic/chemically induced , Epithelium/drug effects , Epithelium/pathology , Zeolites/toxicity , Cell Death/drug effects , Cells, Cultured , Cytotoxins/toxicity , DNA/biosynthesis , DNA/genetics , DNA Damage/genetics , Humans , Microscopy, Electron, Scanning , Time Factors
4.
Med Lav ; 96(4): 360-9, 2005.
Article in English | MEDLINE | ID: mdl-16457433

ABSTRACT

Malignant mesothelioma (MMe) is a seemingly uncommon tumour whose incidence has in fact increased steadily and progressively over the last 30 years. Indeed, an actual "epidemic" is expected in the next 20 years, with over 1300 new cases a year till 2020 at least. Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MMe patients remains dramatically poor. For all the above reasons, translational research is the key to success; indeed, ever increasing knowledge of the molecular mechanisms underlying MMe pathogenesis could lead (and is actually leading) to new, hopefully more active, treatment options. To foster discussion among investigators working in this field, and to exchange different viewpoints concerning the newest advances in MMe pathogenesis and treatment, the VII International Mesothelioma Interest Group (IMIG) meeting was held in Brescia (Italy) between 24 and 26 June 2004 in cooperation with the Italian Group for the Study and Therapy of MMe (GIMe). The aim of this report is to summarize the most significant advances in the different disciplines applied to MMe presented and discussed during the IMIG meeting and how these advances will be changing the perspective of patients with MMe.


Subject(s)
Mesothelioma/therapy , Pleural Neoplasms/therapy , Polyomavirus Infections/therapy , Tumor Virus Infections/therapy , Angiogenesis Inhibitors/therapeutic use , Animals , Antineoplastic Agents/therapeutic use , Asbestos/adverse effects , Carcinogens/toxicity , Combined Modality Therapy/methods , Cytokines/therapeutic use , Genetic Therapy/methods , Humans , Immunotherapy/methods , Mesothelioma/diagnosis , Mesothelioma/drug therapy , Mesothelioma/etiology , Pleural Neoplasms/diagnosis , Pleural Neoplasms/drug therapy , Pleural Neoplasms/etiology , Polyomavirus Infections/diagnosis , Polyomavirus Infections/epidemiology , Polyomavirus Infections/etiology , Protease Inhibitors/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Risk Factors , Simian virus 40/pathogenicity , Societies, Medical , Tumor Virus Infections/diagnosis , Tumor Virus Infections/epidemiology , Tumor Virus Infections/etiology
6.
Curr Pharm Des ; 8(22): 1959-72, 2002.
Article in English | MEDLINE | ID: mdl-12171522

ABSTRACT

Receptor tyrosine kinases (RTKs) are cell surface transmembrane proteins responsible for intracellular signal transduction. They are expressed in several cell types and, after activation by growth factor binding, trigger a series of intracellular pathways, leading to a wide variety of cell responses (e.g., differentiation, proliferation, migration and invasion, angiogenesis, survival). Over-expression and/or structural alteration of RTKs family members are often associated to human cancers and tumor cells are known to use RTK transduction pathways to achieve tumor growth, angiogenesis and metastasis. Therefore, RTKs represent pivotal target in approaches of cancer therapy. A number of small molecules acting as RTK inhibitors have been synthesized by pharmaceutical companies and are under clinical trials, are being analyzed in animal models or have been successfully marketed. Ligand-dependent downregulation of RTKs is a critical step for modulating their activity and the adaptor Cbl has been indicated as the key protein involved in negative regulation of RTKs, such as EGF and HGF receptors. These data suggest novel potential pharmacological targets for the treatment of human malignancies associated to oncogenic activation of RTKs.


Subject(s)
Antineoplastic Agents/pharmacology , Neoplasms/metabolism , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Animals , Antineoplastic Agents/therapeutic use , Enzyme Activation/drug effects , Fusion Proteins, bcr-abl , Hepatocyte Growth Factor/antagonists & inhibitors , Humans , Neoplasms/drug therapy , Protein-Tyrosine Kinases/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors , Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors , Signal Transduction , Stem Cell Factor/antagonists & inhibitors
7.
Br J Cancer ; 86(6): 979-82, 2002 Mar 18.
Article in English | MEDLINE | ID: mdl-11953832

ABSTRACT

Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly, treatment with the DNA hypomethylating agent 5-aza-2'-deoxycytidine induced and up-regulated the expression of the cancer/testis antigen examined in malignant mesothelioma cells. Overall, these findings strongly suggest that cancer/testis antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the clinical use of 5-aza-2'-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.


Subject(s)
Antigens, Neoplasm/analysis , DNA Methylation , Membrane Proteins , Mesothelioma/immunology , Testis/immunology , Animals , Azacitidine/pharmacology , Female , Humans , Immunotherapy , Male , Melanoma-Specific Antigens , Mesothelioma/therapy , Neoplasm Proteins/analysis , Proteins/analysis , Rabbits , Repressor Proteins/analysis
8.
Br J Pharmacol ; 134(6): 1285-95, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11704649

ABSTRACT

1. Macrophage Stimulating Protein (MSP), a serum factor related to Hepatocyte Growth Factor, was originally discovered to stimulate chemotaxis of murine resident peritoneal macrophages. MSP is the ligand for Ron, a member of the Met subfamily of tyrosine kinase receptors. The effects of MSP on human macrophages and the role played in human pathophysiology have long been elusive. 2. We show here that human recombinant MSP (hrMSP) evokes a dose-dependent superoxide anion production in human alveolar and peritoneal macrophages as well as in monocyte-derived macrophages, but not in circulating human monocytes. Consistently, the mature Ron protein is expressed by the MSP responsive cells but not by the unresponsive monocytes. The respiratory burst evoked by hrMSP is quantitatively higher than the one induced by N-formylmethionyl-leucyl-phenylalanine and similar to phorbol myristate acetate-evoked one. 3. To investigate the mechanisms involved in NADPH oxidase activation, leading to superoxide anion production, different signal transduction inhibitors were used. By using the non selective tyrosine kinase inhibitor genistein, the selective c-Src inhibitor PP1, the tyrosine phosphatase inhibitor sodium orthovanadate, the phosphatidylinositol 3-kinase inhibitor wortmannin, the p38 inhibitor SB203580, the MEK inhibitor PD098059, we demonstrate that hrMSP-evoked superoxide production is mediated by tyrosine kinase activity, requires the activation of Src but not of PI 3-kinase. We also show that MAP kinase and p38 signalling pathways are involved. 4. These results clearly indicate that hrMSP induces the respiratory burst in human macrophages but not in monocytes, suggesting for the MSP/Ron complex a role of activator as well as of possible marker for human mature macrophages.


Subject(s)
Caenorhabditis elegans Proteins , Growth Substances/pharmacology , Hepatocyte Growth Factor , Macrophages/drug effects , Proto-Oncogene Proteins , Superoxides/metabolism , Adult , Androstadienes/pharmacology , Animals , Carrier Proteins , Flavonoids/pharmacology , Humans , Imidazoles/pharmacology , Insecta , Macrophages/metabolism , Middle Aged , Monocytes/drug effects , Monocytes/metabolism , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Protein Kinase C/metabolism , Pyridines/pharmacology , Receptors, Drug/metabolism , Respiratory Burst , Signal Transduction , Tetradecanoylphorbol Acetate/pharmacology , Wortmannin
9.
Proc Natl Acad Sci U S A ; 98(21): 12032-7, 2001 Oct 09.
Article in English | MEDLINE | ID: mdl-11572935

ABSTRACT

Recent studies suggested that simian virus 40 (SV40) may cause malignant mesothelioma, although the pathogenic mechanism is unclear. We found that in SV40-positive malignant mesothelioma cells, the hepatocyte growth factor (HGF) receptor (Met) was activated. In human mesothelial cells (HMC) transfected with full-length SV40 DNA (SV40-HMC), Met receptor activation was associated with S-phase entry, acquisition of a fibroblastoid morphology, and the assembly of viral particles. Coculture experiments revealed the ability of SV40-HMC to infect permissive monkey cells (CV-1), HMC, and murine BNL CL cells. Cocultured human and murine SV40-positive cells expressed HGF, showed Met tyrosine phosphorylation and S-phase entry, and acquired a spindle-shaped morphology (spBNL), whereas CV-1 cells were lysed. Cocultured HMC inherited from SV40-HMC the infectivity, as they induced lysis in cocultured CV-1 cells. Treatment with suramin or HGF-blocking antibodies inhibited Met tyrosine phosphorylation in all large T antigen (Tag)-positive cells and reverted the spindle-shaped morphology of spBNL. This finding indicated that Met activation and subsequent biological effects were mediated by an autocrine HGF circuit. This, in turn, was causally related to Tag expression, being induced by transfection with the SV40 early region alone. Our findings suggest that when SV40 infects HMC it causes Met activation via an autocrine loop. Furthermore, SV40 replicates in HMC and infects the adjacent HMC, inducing an HGF-dependent Met activation and cell-cycle progression into S phase. This may explain how a limited number of SV40-positive cells may be sufficient to direct noninfected HMC toward malignant transformation.


Subject(s)
Hepatocyte Growth Factor/metabolism , Mesothelioma/virology , Proto-Oncogene Proteins c-met/metabolism , Simian virus 40/physiology , Virus Replication , Animals , Antigens, Viral, Tumor/genetics , Autocrine Communication , COS Cells , Cell Cycle , Cell Line , Cells, Cultured , Chlorocebus aethiops , Dogs , Enzyme Activation , Epithelium/metabolism , Epithelium/virology , Gene Expression , Humans , Models, Biological , S Phase , Simian virus 40/metabolism
10.
Oncogene ; 19(45): 5208-11, 2000 Oct 26.
Article in English | MEDLINE | ID: mdl-11064459

ABSTRACT

Oncogenic activation of the Ron tyrosine kinase (Macrophage Stimulating Protein receptor) relies on substitutions of two highly conserved residues in the catalytic domain (D1232V and M1254T), which result in ligand-independent activation of the receptor, in vivo tumorigenesis and metastasis. We show here that the Y/F conversion of the Y1317 residue in the kinase domain impairs tumorigenic and metastatic properties of Ron activated by the MEN2B-like mutation (RonM1254T), but not by other two oncogenic substitutions. Furthermore, RonM1254T lacking the multifunctional docking site retains transforming and metastatic activity. These data reveal that the transforming activity of RonM1254T mutant is dependent on Y1317 phosphorylation, suggesting a shift in intramolecular substrate specificity. Consistently, a shift of RonM1254T kinase substrate specificity was observed by in vitro peptide phosphorylation assays and in vivo receptor auto-phosphorylation. The Y1317 phosphorylation elicits by itself activation of PI-3K/Akt and MAPK signalling pathways. Our data indicate that the accomplishment of the full oncogenic phenotype of RonM1254T requires the phosphorylation both of the canonical C-terminal docking site and of the unique Y1317 residue in the tyrosine kinase domain.


Subject(s)
Cell Transformation, Neoplastic/genetics , Protein Serine-Threonine Kinases , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Cell Surface/genetics , Mitogen-Activated Protein Kinases/metabolism , Multiple Endocrine Neoplasia Type 2b/genetics , Mutation , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Receptor, ErbB-2/genetics , Recombinant Fusion Proteins , Signal Transduction , Substrate Specificity
11.
Oncogene ; 17(6): 741-9, 1998 Aug 13.
Article in English | MEDLINE | ID: mdl-9715276

ABSTRACT

Ron (the receptor for Macrophage Stimulating Protein) has never been implicated before in human malignancies or in cell transformation. In this report we show that Ron can acquire oncogenic potential by means of two amino acid substitutions-D1232V and M1254T-affecting highly conserved residues in the tyrosine kinase domain. The same mutations in Kit and Ret have been found associated with two human malignancies, mastocytosis and Multiple Endocrine Neoplasia type 2B (MEN2B), respectively. Both mutations caused Ron-mediated transformation of 3T3 fibroblasts and tumour formation in nude mice. Moreover, cells transformed by the oncogenic Ron mutants displayed high metastatic potential. The Ron mutant receptors were constitutively active and the catalytic efficiency of the mutated kinase was higher than that of wild-type Ron. Oncogenic Ron mutants enhanced activation of the Ras/MAPK cascade with respect to wild type Ron, without affecting the JNK/SAPK pathway. Expression of Ron mutants in 3T3 fibroblasts led to different patterns of tyrosine-phos-phorylated proteins. These data show that point mutations altering catalytic properties and possibly substrate specificity of the Ron kinase may force cells toward tumorigenesis and metastasis.


Subject(s)
Drosophila Proteins , Mitogen-Activated Protein Kinases , Oncogenes , Point Mutation , Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Cell Surface/genetics , 3T3 Cells , Animals , COS Cells , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cell Transformation, Neoplastic/genetics , HeLa Cells , Humans , JNK Mitogen-Activated Protein Kinases , Lung Neoplasms/pathology , Mice , Mice, Nude , Mitogen-Activated Protein Kinase 1 , Neoplasm Metastasis , Phenotype , Phosphorylation , Protein Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-kit/genetics , Proto-Oncogene Proteins c-ret , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Cell Surface/metabolism , Sarcoma, Experimental/pathology , Signal Transduction
12.
Mol Cell Biol ; 16(12): 7072-83, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8943362

ABSTRACT

MET, RON, and SEA are members of a gene family encoding tyrosine kinase receptors with distinctive properties. Besides mediating growth, they control cell dissociation, motility ("scattering"), and formation of branching tubules. While there are transforming counterparts of MET and SEA, no oncogenic forms of RON have yet been identified. A chimeric Tpr-Ron, mimicking the oncogenic form of Met (Tpr-Met) was generated to investigate its transforming potential. For comparison, a chimeric Tpr-Sea was also constructed. Fusion with Tpr induced constitutive activation of the Ron and Sea kinases. While Tpr-Sea was more efficient than Tpr-Met in transformation, Tpr-Ron did not transform NIH 3T3 cells. The differences in the transforming abilities of Tpr-Met and Tpr-Ron were linked to the functional features of the respective tyrosine kinases using the approach of swapping subdomains. Kinetic analysis showed that the catalytic efficiency of Tpr-Ron is five times lower than that of Tpr-Met. Moreover, constitutive activation of Ron resulted in activation of the MAP kinase signaling cascade approximately three times lower than that attained by Tpr-Met. However, constitutive activation of Ron did induce a mitogenic-invasive response, causing cell dissociation, motility, and invasion of extracellular matrices. Tpr-Ron also induced formation of long, unbranched tubules in tridimensional collagen gels. These data show that RON has the potential to elicit a motile-invasive rather than a transformed phenotype.


Subject(s)
Cell Transformation, Neoplastic , Gene Expression Regulation, Neoplastic , Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Cell Surface/genetics , 3T3 Cells , Animals , Cell Division , Mice , Nuclear Pore Complex Proteins
13.
Mol Cell Biol ; 16(10): 5518-26, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8816464

ABSTRACT

The Ron tyrosine kinase receptor shares with the members of its subfamily (Met and Sea) a unique functional feature: the control of cell dissociation, motility, and invasion of extracellular matrices (scattering). The mature Ron protein is a heterodimer of disulfide-linked alpha and beta chains, originated by proteolytic cleavage of a single-chain precursor of 185 kDa. In a human gastric cancer cell line (KATO-III), we found abnormal accumulation of an uncleaved single-chain protein (delta-Ron) of 165 kDa; this molecule is encoded by a transcript differing from the full-length RON mRNA by an in-frame deletion of 49 amino acids in the beta-chain extracellular domain. The deleted transcript originates by an alternatively spliced cassette exon of 147 bp, flanked by two short introns. The delta-Ron tyrosine kinase is constitutively activated by disulfide-linked intracellular oligomerization because it contains an uneven number of cysteine residues. Oligomerization and constitutive tyrosine phosphorylation of the full-size Ron was obtained by site-directed mutagenesis of a single cysteine residue in the region encoded by the cassette exon, mimicking that occurring in the delta-Ron isoform. Inhibition of thiol-mediated intermolecular disulfide bonding prevented delta-Ron oligomerization. The intracellular activation of Ron is followed by acquisition of invasive properties in vitro. These data (i) provide a novel molecular mechanism for posttranscriptional activation of a tyrosine kinase receptor protein and (ii) suggest a role for the Ron receptor in progression toward malignancy.


Subject(s)
Alternative Splicing , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Cell Surface/metabolism , Transcription, Genetic , Base Sequence , Cell Line , DNA Primers , Enzyme Induction , Exons , Genetic Variation , Humans , Introns , Neoplasm Invasiveness , Phenotype , Polymerase Chain Reaction , Receptor Protein-Tyrosine Kinases/biosynthesis , Receptor Protein-Tyrosine Kinases/isolation & purification , Receptors, Cell Surface/biosynthesis , Receptors, Cell Surface/isolation & purification , Recombinant Proteins/biosynthesis , Recombinant Proteins/metabolism , Stomach Neoplasms/genetics , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , TATA Box , Tumor Cells, Cultured
14.
Mol Biol Cell ; 7(4): 495-504, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8730094

ABSTRACT

The mammalian RON and the avian sea genes encode tyrosine kinase receptors of poorly characterized biological functions. We recently identified macrophage-stimulating protein as the ligand for Ron; no ligand has yet been found for Sea. In this work we investigated the biological response to macrophage-stimulating protein in mouse liver progenitor cells expressing Ron. These cells were also transfected with a chimeric cDNA encoding the cytoplasmic domain of Sea, fused to the extracellular domain of Trk (nerve growth factor receptor). In the presence of nanomolar concentrations of the respective ligands, both receptors induced cell "scattering", extracellular matrix invasion, and DNA synthesis. When liver progenitor cells were grown in a tri-dimensional type-I collagen matrix, ligand-induced stimulation of either Ron or Sea induced sprouting of branched cell cords, evolving into ductular-like tubules. The motogenic, mitogenic, and morphogenic responses were also elicited by triggering the structurally related hepatocyte growth factor receptor (Met) but not epidermal growth factor or platelet-derived growth factor receptors. These data show that Ron, Sea, and Met belong to a receptor subfamily that elicits a distinctive biological response in epithelial cells.


Subject(s)
Avian Proteins , Liver/cytology , Protein-Tyrosine Kinases/physiology , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Cell Surface/physiology , Stem Cells/cytology , Amino Acid Sequence , Animals , Base Sequence , Blotting, Western , Cell Differentiation/physiology , Cells, Cultured , Cricetinae , DNA Replication , In Vitro Techniques , Mice , Microscopy, Electron , Molecular Sequence Data , Phenotype , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptor, trkA , Receptors, Cell Surface/genetics , Receptors, Nerve Growth Factor/genetics , Recombinant Fusion Proteins/genetics , Transfection
15.
Oncogene ; 11(12): 2627-37, 1995 Dec 21.
Article in English | MEDLINE | ID: mdl-8545120

ABSTRACT

We previously showed that the proto-oncogene RON encodes the tyrosine kinase receptor for Macrophage Stimulating Protein (MSP), originally isolated as a chemotactic factor for peritoneal macrophages. To elucidate the biological role of MSP we studied the expression of the Ron receptor in vivo, and the response to the factor in vitro. RON specific transcripts were detectable in mouse liver from early embryonal life (day 12.5 p.c.) through adult life. Adrenal gland, spinal ganglia, skin, lung and--unexpectedly--ossification centers of developing mandible, clavicle and ribs were also positive at later stages (day 13.5-16.5 p.c.). From day 17.5 RON was expressed in the gut epithelium and in a specific area of the central nervous system, corresponding to the nucleus of the hypoglossus. In adult mouse tissues RON transcripts were observed in brain, adrenal glands, gastro-intestinal tract, testis and kidney. Epithelial, osteoclast-like and neuroendocrine cells express the Ron receptor and respond to MSP in vitro. In the neuroendocrine PC12 cell line, while NGF induced growth arrest and morphological differentiation, MSP behaved as a strong mitogen. These findings show that the Ron receptor and its ligand are involved in the development of epithelial tissues, bones, and neuroendocrine derivatives driving cells towards the proliferation program.


Subject(s)
Bone Development , Neurosecretory Systems/embryology , Proto-Oncogenes/physiology , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Cell Surface/genetics , Animals , Base Sequence , Cloning, Molecular , Epithelium/embryology , Female , Humans , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Proto-Oncogene Mas , Proto-Oncogene Proteins c-met , RNA, Messenger/analysis , Transcription, Genetic
16.
Arterioscler Thromb Vasc Biol ; 15(11): 1857-65, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7583565

ABSTRACT

Hepatocyte growth factor (HGF) is a powerful motogen and mitogen for epithelial cells. The factor is a 90-kD heterodimer composed of an alpha chain containing four kringle motifs and a beta chain showing structural homologies with serine proteases. It is, however, devoid of enzymatic activity. Recently, it has been reported that HGF activates migration and proliferation of endothelial cells and is angiogenic. In this article we discuss (1) the molecular domains of HGF required to activate in vitro and in vivo endothelial cells, studied by use of molecular mutants, and (2) the characteristics of the angiogenic response to HGF in an experimental model system of implanted reconstituted basement membrane (Matrigel). Two groups of mutants were made and used in vitro and in vivo: one with deletions of kringle domains and one with substitution at the cleavage site of the HGF precursor. In vitro, HGF variants containing only the first two (HGF-NK2) or the first three kringles (HGF-NK3) of the alpha chain did not induce proliferation of endothelial cells even if used at concentration 160-fold higher than that optimal for HGF (0.05 nmol/L). High concentrations of these mutants (4 to 8 nmol/L) activated a little endothelial cell motogenic response that was 60% lower than that elicited by HGF. Substitution of Arg 489 with Gln 489 in the HGF precursor generated an uncleavable single-chain factor, unable to induce either endothelial cell migration or proliferation. In vivo, HGF induced a dose-dependent angiogenic response, which was enhanced by heparin.


Subject(s)
Endothelium, Vascular/drug effects , Hepatocyte Growth Factor/pharmacology , Neovascularization, Physiologic/drug effects , Protein-Tyrosine Kinases/metabolism , Animals , Base Sequence , Cell Division/drug effects , Cell Movement/drug effects , Cells, Cultured , Drug Synergism , Endothelium, Vascular/cytology , Endothelium, Vascular/enzymology , Enzyme Activation , Female , Heparin/pharmacology , Hepatocyte Growth Factor/genetics , Humans , Mice , Mice, Inbred DBA , Molecular Sequence Data , Mutation
17.
EMBO J ; 13(15): 3524-32, 1994 Aug 01.
Article in English | MEDLINE | ID: mdl-8062829

ABSTRACT

RON, a cDNA homologous to the hepatocyte growth factor (HGF) receptor gene (MET), encodes a putative tyrosine kinase. Here we show that the RON gene is expressed in several epithelial tissues as well as in granulocytes and monocytes. The major RON transcript is translated into a glycosylated single chain precursor, cleaved into a 185 kDa heterodimer (p185RON) of 35 (alpha) and 150 kDa (beta) disulfide-linked chains, before exposure at the cell surface. The Ron beta-chain displays intrinsic tyrosine kinase activity in vitro, after immunoprecipitation by specific antibodies. In vivo, tyrosine phosphorylation of p185RON is induced by stimulation with macrophage stimulating protein (MSP), a protease-like factor containing four 'kringle' domains, homologous to HGF. In epithelial cells, MSP-induced tyrosine phosphorylation of p185RON is followed by DNA synthesis. p185RON is not activated by HGF, nor is the HGF receptor activated by MSP in biochemical and biological assays. p185RON is also activated by a pure recombinant protein containing only the N-terminal two kringles of MSP. These data show that p185RON is a tyrosine kinase activated by MSP and that it is member of a family of growth factor receptors with distinct specificities for structurally related ligands.


Subject(s)
Growth Substances/pharmacology , Protein Conformation , Proto-Oncogene Proteins , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Cell Surface/metabolism , Base Sequence , Cell Movement/drug effects , Cloning, Molecular , DNA Replication/drug effects , Epithelial Cells , Growth Substances/genetics , Hepatocyte Growth Factor/pharmacology , Humans , Kringles , Molecular Sequence Data , Organ Specificity , Phosphorylation/drug effects , Protein Precursors/biosynthesis , RNA, Messenger/analysis , Receptor Protein-Tyrosine Kinases/chemistry , Receptors, Cell Surface/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , Transcription, Genetic , Tumor Cells, Cultured , Tyrosine/metabolism
18.
Oncogene ; 9(4): 1091-9, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8134112

ABSTRACT

Exogenous HGF/SF converts subconfluent cultures of NBT-II epithelial carcinoma cells into mobile fibroblast-like cells while being only mitogenic for cells maintained at high density. To investigate the potential role of such factor in tumor progression, we generated HGF/SF-producing NBT-II cells by transfection with an expression plasmid containing human HGF/SF cDNA. HGF/SF-producing cells also exhibit a fibroblastic phenotype. Media conditioned by these cells are potent inducers of in vitro tubulogenesis which can be inhibited with specific anti-HGF/SF antibodies; these antibodies are also able to reverse the scattered phenotype of the HGF/SF-producing cells. In addition spheroids of HGF/SF-producing cells are dispersed into 3D collagen gels suggesting an increase of invasive properties of these cells. When injected in nude mice, these HGF/SF-producing cells induce tumors appearing more rapidly than did those obtained with untransfected cells. These results show that HGF/SF can promote motility and invasive properties of NBT-II bladder carcinoma cells and also confers a tumorigenic advantage when acting as an autocrine factor.


Subject(s)
Hepatocyte Growth Factor/pharmacology , Urinary Bladder Neoplasms/pathology , Animals , Antibody Specificity , Cell Adhesion/drug effects , Cell Division/drug effects , Culture Media, Conditioned/pharmacology , Female , Fibroblasts/pathology , Humans , Mice , Mice, Nude , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasms, Experimental/etiology , Rats , Transfection , Tumor Cells, Cultured
19.
J Biol Chem ; 269(17): 12846-51, 1994 Apr 29.
Article in English | MEDLINE | ID: mdl-8175699

ABSTRACT

The c-MET proto-oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), also known as scatter factor, a potent mitogen and motogen for epithelial cells. The level of the HGF receptor expressed by epithelial cells varies in different growth conditions, being lower in growth arrested confluent monolayers and higher in growing sparse cells. The amount of HGF receptor mRNA increases from 3- to 5-fold after stimulation of confluent monolayers by serum and up to 10-fold after stimulation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate (TPA). An increased level of the receptor mRNA was also observed after cell stimulation with nanomolar concentration of HGF itself. The effect was transient, dose, and time-dependent. Transcription of a reporter gene under control of the cloned 297 base pair c-MET promoter was also stimulated by serum, TPA, or HGF. The accumulation of specific mRNA is followed by appearance of the HGF receptor precursor protein, which is further processed to the receptor mature form. After HGF stimulation, HGF receptor expression follows c-FOS and c-JUN induction with a peak approximately 4 h. Pretreatment with the protein synthesis inhibitor puromycin strongly reduced the response to HGF, while cycloheximide alone increased the level of the receptor mRNA. These data show that c-MET behaves as a delayed early-response gene and suggest that the HGF response is autoamplified by inducing the specific receptor.


Subject(s)
Hepatocyte Growth Factor/pharmacology , Receptor Protein-Tyrosine Kinases/biosynthesis , Blood , Cell Division , Epithelium/metabolism , Genes, Immediate-Early , Humans , Promoter Regions, Genetic , Protein Biosynthesis , Protein Processing, Post-Translational , Proto-Oncogene Mas , Proto-Oncogene Proteins c-met , RNA, Messenger/metabolism , Receptor Protein-Tyrosine Kinases/drug effects , Receptor Protein-Tyrosine Kinases/genetics , Tetradecanoylphorbol Acetate/pharmacology , Tumor Cells, Cultured
20.
J Biol Chem ; 268(24): 18176-80, 1993 Aug 25.
Article in English | MEDLINE | ID: mdl-7688741

ABSTRACT

The receptor for the growth and motility factor, hepatocyte growth factor/scatter factor (HGF/SF), is a transmembrane tyrosine kinase encoded by the MET oncogene. Previous work has shown that receptor phosphorylation on tyrosine is critical for both kinase activation and association with intracellular signal transducers. In this paper, we report that a protein tyrosine phosphatase activity (PTP) coprecipitates with the HGF/SF receptor. The associated PTP activity correlates with the kinase activation of the receptor, increasing up to 5-fold over the basal level after HGF/SF stimulation. The increase is reversible and time- and dose-dependent. A comparable level of activity is associated with constitutively tyrosine-phosphorylated receptors immunoprecipitated from cells where the MET oncogene is amplified and overexpressed. In these cells, a parallel decrease in PTP activity is observed after inhibition of receptor tyrosine phosphorylation following protein kinase C activation. The associated PTP activity is effective in dephosphorylating the HGF/SF receptor. These data show that a protein tyrosine phosphatase is functionally coupled to the HGF/SF receptor.


Subject(s)
Hepatocyte Growth Factor/metabolism , Protein Tyrosine Phosphatases/metabolism , Proto-Oncogene Proteins/metabolism , Cell Line , Cell Membrane , Chromatography, Gel , Gene Expression , Hepatocyte Growth Factor/pharmacology , Humans , Kinetics , Oncogenes , Phosphotyrosine , Protein Kinase C/metabolism , Protein Tyrosine Phosphatases/isolation & purification , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/isolation & purification , Proto-Oncogene Proteins c-met , Proto-Oncogenes , Recombinant Proteins/metabolism , Time Factors , Transfection , Tumor Cells, Cultured , Tyrosine/analogs & derivatives , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...